Results 131 to 140 of about 5,563 (240)

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source

AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE (R)) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)

, 2019
AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE (R)) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM ...
Erik Rasmussen (793615), Mustafa Khasraw (13078896), Cyrus Sayehli (13470631), Mark A Rosenthal (13470622), Walter M Fiedler (13470634), Myra E van Linde (13470628), Sabine Stienen (13470637), Martin Wermke (400912), Carmen Balana (13470625), Christophe Massard (120966), Ingo K Mellinghoff (13470493), Agnes Ang (5409845), Johannes Kast (1408891), Timothy F Cloughesy (13470640)   +13 more
core  

Is universal CAR T‐cell referral absolutely required for transplant‐ineligible patients with primary refractory or early relapsed DLBCL?

British Journal of Haematology, EarlyView.
Maria Dimou, Theodoros P. Vassilakopoulos   +1 more
wiley   +1 more source

Seventh Åland Island Meeting on von Willebrand Disease

Haemophilia, EarlyView.
ABSTRACT Introduction The seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024. Aim The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD.
Riitta Lassila, Ruben Bierings, Nathan T. Connell, Fernando F. Corrales‐Medina, Augusto B. Federici, Veronica H. Flood, Floor Heubel‐Moenen, Jill M. Johnsen, Geoffrey Kuppens, Davide Matino, Carolyn Millar, Ingmar Schoen, Anish Sharda, Robert F. Sidonio Jr, Alok Srivastava, Timea Szanto, Angela C. Weyand, Erik Berntorp   +17 more
wiley   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review

Immunotherapy Advances
Abstract In the past decade, T-cell-based immunotherapies have grown to become some of the most promising treatments for cancer. Following the success of immune checkpoint inhibitors, other T-cell-based therapies emerged including CAR-T cells and bispecific T-cell engagers (BiTEs).
Dewaele, L, Fernandes, RA
openaire   +2 more sources

The synthesis of amphiphilic polyethyleneimine/calcium phosphate composites for bispecific T-cell engager based immunogene therapy

, 2018
Bispecific T-cell engagers (BiTEs) are single chain variable fragments, which could connect the surface antigen on cancer cells and CD3 ligands on T cells, and then engage the T cells for cancer immunotherapy.
Yunhong Liu, Xiaojuan Pang, Xiaohu Hou, Jing Zhao, Zhiyong Wang, Zhi-ying Chen, Pingzhang Chen, Peifa Zhang, Ping Chen, Cheng-yi He   +9 more
core   +1 more source

BCL‐2 and MCL1 co‐inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A‐rearranged acute lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Mawar Karsa, Ayu Karsa, Dayna Spurling, Lin Xiao, Emma Ronca, Angelika Bongers, Weiman Gao, Andrew J. Gifford, Ali El‐Ayoubi, Laurence C. Cheung, Rishi S. Kotecha, Richard B. Lock, Charis E. Teh, Guillaume Lessene, Murray D. Norris, Andrew Wei, Michelle Haber, Michelle J. Henderson, Donia M. Moujalled, Klaartje Somers   +19 more
wiley   +1 more source

Toxoplasmosis Beyond Transplantation: Diagnostic and Prevention Challenges in a Patient Receiving Targeted Immunomodulators

Transplant Infectious Disease, EarlyView.
ABSTRACT Toxoplasmosis has long been recognized as a serious complication in immunocompromised host, particularly those with advanced HIV/AIDS, hematopoietic stem‐cell transplantation (HSCT), solid‐organ transplant (SOT), and hematological malignancies. The rapid expansion of targeted immunomodulators, including chimeric antigen receptor T‐cell (CAR‐T)
Joy Mouanes‐Abelin, Christelle Pomares, José G. Montoya, Morgane Pondrom, Lucille DE MARIA, Andrea J. Zimmer, Carlos A. Gomez   +6 more
wiley   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, Volume 117, Issue 2, Page 320-337, August 2026.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source